Myelodysplastic syndromes (MDS) consist of a heterogeneous group of myeloid neoplasms
characterized by inefficient hematopoiesis, variable cytopenias and a considerable risk of …

Treatment of older adults with acute myeloid leukemia (AML) or myelodysplastic syndromes
(MDS) is challenging because of disease morbidity and associated treatments. Both …

The hypomethylating agents (HMAs) azacitidine and decitabine have been the de facto
standard of care for patients with acute myeloid leukemia (AML) who are unfit for intensive …

Hospice provides high-quality end-of-life care, but patients with leukemias use hospice
services less frequently than those with solid tumors. Transfusion dependence (TD) may …

The hypomethylating agents (HMA s) azacitidine and decitabine are both approved for
treatment of myelodysplastic syndromes (MDS) in the USA. In Europe, decitabine is not …

Established prognostic tools in patients with myelodysplastic syndromes (MDS) were largely
derived from untreated patient cohorts. Although azanucleosides are standard therapies for …

Myelosysplastic syndromes (MDS) include a heterogeneous group of clonal myeloid
neoplasms characterized by ineffective hematopoiesis leading to blood cytopenias and a …

Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid disorders
characterized by cytopenias and increased risk of acute leukemia transformation. Prognosis …

Aims: Iron overload adversely affects patients with myelodysplastic syndromes (MDS), but
benefits of iron chelation therapy have not been clearly demonstrated. We examined the …

Beyond hypomethylating agents failure in patients with myelo... : Current Opinion in
Hematology Beyond hypomethylating agents failure in patients with myelodysplastic …